Notably, in transgenic mice with prolactin-mediated androgen signaling deficiency, antioxidant therapy remained effective, highlighting OS inhibition as a viable strategy for androgen-independent BPH (105). The gene discussed is PRL; the disease is benign prostatic hyperplasia.